Heart disease and stroke statistics 2023 update from the American Heart Association-implications for nephrology

Nicola C Edwards1,2, Charles J Ferro3,4, Jonathan N Townend3,4

  • 1Green Lane Cardiovascular Service, Te Tuka Tumai, Auckland, New Zealand.

Insights

This report summarizes key cardiovascular disease statistics from the AHA and NIH, focusing on chronic kidney disease (CKD) populations and disparities. It highlights the impact of environmental, behavioral, and COVID-19 factors on heart health.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Public Health Statistics

Background:

  • The American Heart Association (AHA) and National Institutes of Health (NIH) release an annual statistical report on cardiovascular disease (CVD) and risk factors in the USA.
  • This comprehensive report serves as a critical resource for healthcare professionals and researchers globally, despite its US-centric data.
  • This analysis specifically focuses on aspects relevant to nephrologists, emphasizing the intersection of cardiovascular and renal disease.

Approach:

  • The authors review the latest AHA/NIH statistical report, highlighting data pertinent to nephrology.
  • Key areas examined include cardiovascular trends in the general and chronic kidney disease (CKD) populations.
  • The analysis also addresses ethnic/socioeconomic disparities, environmental/behavioral drivers of CVD, and the impact of COVID-19 on heart health.

Key Points:

  • Emerging cardiovascular data signals in general and CKD populations are presented.
  • Ethnic and socioeconomic disparities in cardiovascular health are discussed.
  • Environmental, behavioral factors, and the AHA's Life Essential 8 score are analyzed in relation to CVD.
  • The direct and indirect impacts of COVID-19 on cardiovascular health are examined.

Conclusions:

  • The report underscores the significant overlap between cardiovascular and renal diseases.
  • There is a need for similar comprehensive statistical data on CKD, potentially linked with existing cardiovascular datasets.
  • The findings emphasize the importance of addressing disparities and modifiable risk factors to improve cardiovascular and kidney health outcomes.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
395
Regulation of Stroke Volume01:27

Regulation of Stroke Volume

The regulation of stroke volume, which is the amount of blood the heart pumps out during each heartbeat, is critical for maintaining a healthy circulatory system. Stroke volume is influenced by three main factors: preload, contractility, and afterload.
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
3.3K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K